Molecular imaging of tumor microenvironment: Challenges and perspectives

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 54, Issue 3, 2010, Pages 249-258

  Del Vecchio, S ^a,b   Zannetti, A ^b   Iommelli, F ^b   Lettieri, A ^b   Brunetti, A ^a,b   Salvatore, M ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

Author keywords

Extracellular matrix; Matrix metalloproteinases; Molecular imaging

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 2 (N BENZYL 4 METHOXYBENZENESULFONAMIDO) N HYDROXY 3 METHYLBUTANAMIDE; CGS 27023 A; CGS 27023A; COPPER 64; CYCLIN D1; CYTOKINE; FIBROBLAST GROWTH FACTOR; FIBRONECTIN; GADOLINIUM; GELATINASE A; GELATINASE B; GROWTH FACTOR; IODINE 124; MESSENGER RNA; NANOPARTICLE; PROTEINASE; SCATTER FACTOR; SOMATOMEDIN; TRACER; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR;

ARTHRITIS; BREAST ADENOCARCINOMA; CANCER CELL; CELL INFILTRATION; CELL INTERACTION; ENZYME SYNTHESIS; EXTRACELLULAR FLUID; GLYCOLYSIS; HOST CELL; HUMAN; HYPOXIA; IMMUNOCOMPETENT CELL; KAPOSI SARCOMA; MOLECULAR IMAGING; MOLECULAR PROBE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PH; PHENOTYPE; REVIEW; TUMOR MICROENVIRONMENT;

ANIMALS; EXTRACELLULAR MATRIX; GLYCOLYSIS; HUMANS; HYDROGEN-ION CONCENTRATION; MATRIX METALLOPROTEINASES; MOLECULAR IMAGING; TUMOR MICROENVIRONMENT;

EID: 77958610812     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Bhowmick NA, Moses HL. Tumor-stroma interactions. Curr Opin Genet Dev 2005;15:97-101.
2. Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004;4:839-49.
3. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009;9:239-52.
4. Pietras K, Ostman A. Hallmarks of cancer: Interactions with the tumor stroma. Exp Cell Res 2010; doi:10.10l6/j.yexcr.2010.02.045.
5. Cretu A, Brooks PC. Impact of the non-cellular tumor microenvironment on metastasis: potential therapeutic and imaging opportunities. J Cell Physiol 2007;213:391-402.
6. Dang CV, Kim JW, Gao P, Yustein J. The interplay between MYC and HIF in cancer. Nat Rev Cancer 2008;8:51-6.
7. Gatenby RA, Gillies RJ. A microenvironmental model of carcinogenesis. Nat Rev Cancer 2008;8:56-61.
8. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 2008,8:705-13.
9. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891-9.
10. Mason RB, Zhao D, Pecheco-Torres J, Cui W, Kodibagkar VD, Gulaka PK et al. Multimodality imaging of hypoxia in preclinical settings. Q J Nucl Med Mol Imaging 2010;54:259-80.
11. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
12. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 2008;49 Suppl 2-24S-42S.
13. Plathow C, Weber WA. Tumor cell metabolism imaging. J Nucl Med 2008;49 Suppl 2:43S-63S.
14. Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009;9:665-74.
15. Stubbs M, McSheehy PM, Griffiths JR. Causes and consequences of acidic pH in tumors: a magnetic resonance study. Adv Enzyme Regul 1999;39:13-30.
16. Raghunand N, Gillies RJ. pH and chemotherapy. Novartis Found Symp 2001;240:199-211; discussion 65-8.
17. Rajendran JG, Krohn KA. Imaging hypoxia and angiogenesis in tumors. Radiol Clin North Am 2005;43:169-87.
18. Griffiths JR, Stevens AN, Iles RA, Gordon RE, Shaw D. 31P-NMR investigation of solid tumours in the living rat. Biosci Rep 1981;1:319-25.
19. Evanochko WT, Ng TC, Lilly MB, Lawson AJ, Corbett TH, Durant JR et al. In vivo 31P NMR study of the metabolism of murine mammary 16/C adenocarcinoma and its response to chemotherapy, x-radiation, and hyperthermia. Proc Natl Acad Sci U S A 1983;80:334-8.
20. Griffiths JR. Are cancer cells acidic? Br J Cancer 1991;64:425-7.
21. Gillies RJ, Liu Z, Bhujwalla Z. 31P-MRS measurements of extra-cellular pH of tumors using 3-aminopropylphosphonate. Am J Physiol 1994;267:C195-203.
22. Gil S, Zaderenzo P, Cruz F, Cerdan S, Ballesteros P. Imidazol-1- ylalkanoic acids as extrinsic 1H NMR probes for the determination of intracellular pH, extracellular pH and cell volume. Bioorg Med Chem 1994;2:305-14.
23. Zhou J, Payen JF, Wilson DA, Traystman RJ, van Zijl PC. Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI. Nat Med 2003;9:1085-90.
24. Aime S, Barge A, Delli Castelli D, Fedeli F, Mortillaro A, Nielsen FU et al. Paramagnetic lanthanide(III) complexes as pH-sensitive chemical exchange saturation transfer (CEST) contrast agents for MRI applications. Magn Reson Med 2002;47:639-48.
25. Garcia-Martin ML, Martinez GV, Raghunand N, Sherry AD, Zhang S, Gillies RJ. High resolution pH(e) imaging of rat glioma using pH-dependent relaxivity. Magn Reson Med 2006;55:309-15.
26. Gallagher FA, Kettunen MI, Day SE, Hu DE, Ardenkjaer-Larsen JH, Zandt R et al. Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate. Nature 2008;453:940-3.
27. Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, et al. Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR. Proc Nad Acad Sci U S A 2003;100:10158-63.
28. Andreev OA, Dupuy AD, Segala M, Sandugu S, Serra DA, Chichester CO et al. Mechanism and uses of a membrane peptide that targets tumors and other acidic tissues in vivo. Proc Natl Acad Sci U S A 2007;104:7893-8.
29. Urano Y, Asanuma D, Hama Y, Koyama Y, Barrett T, Kamiya M et al. Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med 2009;15:104-9.
30. Vavere AL, Biddlecombe GB, Spees WM, Garbow JR, Wijesinghe D, Andreev OA et al. A novel technology for the imaging of acidic prostate tumors by positron emission tomography. Cancer Res 2009;69:4510-6.
31. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
32. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010; 11:23-36.
33. Bremer C, Tung CH, Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 2001;7:743-8.
34. Scherer RL, VanSaun MN, McIntyre JO, Matrisian LM. Optical imaging of matrix metalloproteinase-7 activity in vivo using a proteolytic nanobeacon. Mol Imaging 2008;7:118-31.
35. Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci U S A 2004,101:17867-72.
36. Olson ES, Aguilera TA, Jiang T, Ellies LG, Nguyen QT, Wong EH et al. In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr Biol (Camb) 2009;1:382-93.
37. Breyholz HJ, Wagner S, Levkau B, Schober O, Schafers M, Kopka K. A 18F-radiolabeled analogue of CGS 27023A as a potential agent for assessment of matrix-metalloproteinase activity in vivo. Q J Nucl Med Mol Imaging 2007;51:24-32.
38. Zheng QH, Fei X, Liu X, Wang JQ, Stone KL, Martinez TD et al. Comparative studies of potential cancer biomarkers carbon-11 labeled MMP inhibitors (S)-2-(4′-[11C]methoxybiphenyl-4-sulfonylamino)-3-methylbutyric acid and N-hydroxy-(R)-2-[[(4′-[11C]methoxyphenyl)sulfonyl]benzylamino] -3-methylbut anamide. Nucl Med Biol 2004;31:77-85.
39. Kopka K, Breyholz HJ, Wagner S, Uw MP, Riemann B, Schroer S, et al. Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo. Nucl Med Biol 2004;31:257-67.
40. Schafers M, Riemann B, Kopka K, Breyholz HJ, Wagner S, Schafers KP et al. Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation 2004;109:2554-9.
41. Wagner S, Breyholz HJ, Holtke C, Faust A, Schober O, Schafers M et al. A new 18F-labelled derivative of the MMP inhibitor CGS 27023A for PET: radiosynthesis and initial small-animal PET studies. Appl Radiat Isot 2009;67:606-10.
42. Kulasegaram R, Giersing B, Page CJ, Blower PJ, Williamson RA, Peters BS et al. In vivo evaluation of 111In-DTPA-N-TIMP-2 in Kaposi sarcoma associated with HIV infection. Eur J Nucl Med 2001;28:756-61.
43. Lepage M, Dow WC, Melchior M, You Y, Fingleton B, Quarles CC et al. Noninvasive detection of matrix metalloproteinase activity in vivo using a novel magnetic resonance imaging contrast agent with a solubility switch. Mol Imaging 2007;6:393-403.
44. Lebel R, Jastrzebska B, Therriault H, Cournoyer MM, McIntyre JO, Escher E et al. Novel solubility-switchable MRI agent allows the noninvasive detection of matrix metalloproteinase-2 activity in vivo in a mouse model. Magn Reson Med 2008;60:1056-65.
45. Olson ES, Jiang T, Aguilera TA, Nguyen QT, Ellies LG, Scadeng M et al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci U S A 2010; 107:4311-6.
46. D'Alessio S, Blasi F. The urokinase receptor as an entertainer of signal transduction. Front Biosci 2009;14:4575-87.
47. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 2008;34:122-36.
48. Del Vecchio S, Stoppelli MP, Carriero MV, Fonti R, Massa O, Li PY et al. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels. Cancer Res 1993;53:3198-206.
49. Zannetti A, Del Vecchio S, Carriero MV, Fonti R, Franco P, Botti G et al. Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma. Cancer Res 2000;60:1546-51.
50. Shariat SF, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 2007;25:349-55.
51. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sorensen S, Dano K, et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999,91.869-74.
52. Li ZB, Niu G, Wang H, He L, Yang L, Ploug M et al. Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by microPET. Clin Cancer Res 2008;14:4758-66.
53. Yang L, Peng XH, Wang YA, Wang X, Cao Z, Ni C et al. Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin Cancer Res 2009;15:4722-32.
54. Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003;9:571-9.
55. Berndorff D, Borkowski S, Moosmayer D, Viti F, Muller-Tiemann B, Sieger S et al. Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments. J Nucl Med 2006;47:1707-16.
56. Tijink BM, Perk LR, Budde M, Stigter-van Walsum M, Visser GW, Kloet RW et al. (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy. Eur J Nucl Med Mol Imaging 2009;36:1235-44.
57. Rossin R, Berndorff D, Friebe M, Dinkelborg LM, Welch MJ. Small-animal PET of tumor angiogenesis using a (76)Br-labeled human recombinant antibody fragment to the ED-B domain of fibronectin. J Nucl Med 2007;48:1172-9.
58. Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett 2006;244:143-63.
59. Herold-Mende C, Mueller MM, Bonsanto MM, Schmitt HP, Kunze S, Steiner HH. Clinical impact and functional aspects of tenascin-C expression during glioma progression. Int J Cancer 2002,98: 362-9.
60. Riva P, Franceschi G, Riva N, Casi M, Santimaria M, Adamo M. Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach. Eur J Nucl Med 2000;27:601-9.
61. Akabani G, Reardon DA, Coleman RE, Wong TZ, Metzler SD, Bowsher JE et al. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J Nucl Med 2005;46:1042-51.
62. Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS et al. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 2008;49:30-8.
63. Paganelli G, Grana C, Chinol M, Cremonesi M, De Cicco C, De Braud F et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 1999;26:348-57.
64. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, 2nd et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 2006;24:115-22.
65. Hicke BJ, Stephens AW, Gould T, Chang YF, Lynott CK, Heil J et al. Tumor targeting by an aptamer. J Nucl Med 2006;47:668-78.
66. Zhu L, Niu G, Fang X, Chen X. Preclinical molercular imaging of tumor angiogenesis. Q J Nucl Med Mol Imaging 2010;54:291-308.
67. Hay RV, Cao B, Skinner RS, Su Y, Zhao P, Gustafson MF et al. Nuclear imaging of Met-expressing human and canine cancer xenografts with radiolabeled monoclonal antibodies (MetSeek). Clin Cancer Res 2005;11:7064s-9s.
68. Perk LR, Stigter-van Walsum M, Visser GW, Kloet RW, Vosjan MJ, Leemans CR et al. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging 2008;35:1857-67.
69. Shaharabany M, Abramovitch R, Kushnir T, Tsarfaty G, Ravid-Megido M, Horev J et al. In vivo molecular imaging of met tyrosine kinase growth factor receptor activity in normal organs and breast tumors. Cancer Res 2001;61:4873-8.
70. Cornelissen B, McLarty K, Kersemans V, Reilly RM. The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin). Nucl Med Biol 2008;35:645-53.
71. Tian X, Aruva MR, Zhang K, Shanthly N, Cardi CA, Thakur ML et al. PET imaging of CCND1 mRNA in human MCF7 estrogen receptor positive breast cancer xenografts with oncogene-specific [64Cu]chelator-peptide nucleic acid-IGF1 analog radiohybridization probes. J Nucl Med 2007;48:1699-707.
72. Koizumi K, Hojo S, Akashi T, Yasumoto K, Saiki I. Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci 2007;98:1652-8.
73. Jacobson O, Weiss ID, Szajek L, Farber JM, Kiesewetter DO. 64Cu-AMD3100 - a novel imaging agent for targeting chemokine receptor CXCR4. Bioorg Med Chem 2009;17:1486-93.
74. Nimmagadda S, Pullambhatla M, Pomper MG. Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT. J Nucl Med 2009;50:1124-30.